tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), BeiGene (BGNE) and Catalent (CTLT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Exelixis (EXELResearch Report), BeiGene (BGNEResearch Report) and Catalent (CTLTResearch Report).

Exelixis (EXEL)

Wells Fargo analyst Derek Archila maintained a Buy rating on Exelixis today and set a price target of $28.00. The company’s shares closed last Friday at $20.22.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 8.4% and a 43.7% success rate. Archila covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Arvinas Holding Company, and Rhythm Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Exelixis with a $26.44 average price target, a 30.2% upside from current levels. In a report issued on February 6, Barclays also maintained a Buy rating on the stock with a $25.00 price target.

See the top stocks recommended by analysts >>

BeiGene (BGNE)

Jefferies analyst Kelly Shi maintained a Buy rating on BeiGene on February 9 and set a price target of $287.00. The company’s shares closed last Friday at $146.98, close to its 52-week low of $132.95.

According to TipRanks.com, Shi is a 2-star analyst with an average return of 0.0% and a 42.5% success rate. Shi covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Gracell Biotechnologies, and Autolus Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BeiGene with a $243.67 average price target, implying a 68.5% upside from current levels. In a report issued on February 6, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $185.00 price target.

Catalent (CTLT)

Jefferies analyst David Windley maintained a Hold rating on Catalent yesterday and set a price target of $63.50. The company’s shares closed last Friday at $56.71.

According to TipRanks.com, Windley is a 5-star analyst with an average return of 13.1% and a 66.4% success rate. Windley covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Fortrea Holdings Inc., and Stevanato Group.

Currently, the analyst consensus on Catalent is a Hold with an average price target of $53.65, implying a -5.4% downside from current levels. In a report issued on February 5, Nephron also downgraded the stock to Hold.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on EXEL:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles